Back to Search Start Over

Complex Large-Bore Radial percutaneous coronary intervention: Rationale of the COLOR trial study protocol

Authors :
Juan F. Iglesias
Paul Knaapen
Thomas A. Meijers
Adel Aminian
Maurits T. Dirksen
Koen Teeuwen
Joseph Dens
Niels van Royen
René J. van der Schaaf
Thomas Schmitz
A T Marcel Gosselink
Pierfrancesco Agostoni
Maarten A.H. van Leeuwen
Marleen H. van Wely
Jan-Henk E. Dambrink
Vincent Roolvink
Sudhir Rathore
Jan Paul Ottervanger
Renicus S Hermanides
Source :
BMJ Open, Vol 10, Iss 7 (2020), Meijers, T A, Aminian, A, Teeuwen, K, van Wely, M, Schmitz, T, Dirksen, M T, van der Schaaf, R J, Iglesias, J F, Agostoni, P, Dens, J, Knaapen, P, Rathore, S, Ottervanger, J P, Dambrink, J-H E, Roolvink, V, Gosselink, A T M, Hermanides, R S, van Royen, N & van Leeuwen, M A H 2020, ' Complex Large-Bore Radial percutaneous coronary intervention: Rationale of the COLOR trial study protocol ', BMJ Open, vol. 10, no. 7, e038042 . https://doi.org/10.1136/bmjopen-2020-038042, BMJ Open, 10, 7, BMJ Open, 10, BMJ Open
Publication Year :
2020

Abstract

IntroductionThe radial artery has become the standard access site for percutaneous coronary intervention (PCI) in stable coronary artery disease and acute coronary syndrome, because of less access site related bleeding complications. Patients with complex coronary lesions are under-represented in randomised trials comparing radial with femoral access with regard to safety and efficacy. The femoral artery is currently the most applied access site in patients with complex coronary lesions, especially when large bore guiding catheters are required. With slender technology, transradial PCI may be increasingly applied in patients with complex coronary lesions when large bore guiding catheters are mandatory and might be a safer alternative as compared with the transfemoral approach.Methods and analysisA total of 388 patients undergoing complex PCI will be randomised to radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator. The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention. Procedural success and major adverse cardiovascular events up to 1 month will also be compared between both groups.Ethics and disseminationEthical approval for the study was granted by the local Ethics Committee at each recruiting center (‘Medisch Ethische Toetsing Commissie Isala Zwolle’, ‘Commissie voor medische ethiek ZNA’, ‘Comité Medische Ethiek Ziekenhuis Oost-Limburg’, ‘Comité d’éthique CHU-Charleroi-ISPPC’, ‘Commission cantonale d'éthique de la recherche CCER-Republique et Canton de Geneve’, ‘Ethik Kommission de Ärztekammer Nordrhein’ and ‘Riverside Research Ethics Committee’). The trial outcomes will be published in peer-reviewed journals of the concerned literature.Trial registration numberNCT03846752.

Details

Language :
English
ISSN :
20446055
Volume :
10
Issue :
7
Database :
OpenAIRE
Journal :
BMJ Open
Accession number :
edsair.doi.dedup.....74bff848181497e74675971a87368906
Full Text :
https://doi.org/10.1136/bmjopen-2020-038042